The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Trial of solanezumab in preclinical Alzheimer's disease
Open accessAbstract
Trials of monoclonal antibodies that target various forms of amyloid at different stages of Alzheimer’s disease have had mixed results. Download a PDF of the Research Summary. We tested solanezumab, which targets monomeric amyloid, in a phase 3 trial involving persons with preclinical Alzheimer’s disease. Persons 65 to 85 years of age with a global Clinical Dementia Rating score of 0 (range, 0 to 3, with 0 indicating no cognitive impairment and 3 severe dementia), a score on the Mini–Mental State Examination of 25 or more (range, 0 to 30, with lower scores indicating poorer cognition), and elevated brain amyloid levels on 18F-florbetapir positron-emission tomography (PET) were enrolled. Participants were randomly assigned in a 1:1 ratio to receive solanezumab at a dose of up to 1600 mg intravenously every 4 weeks or placebo. The primary end point was the change in the Preclinical Alzheimer Cognitive Composite (PACC) score (calculated as the sum of four z scores, with higher scores indicating better cognitive performance) over a period of 240 weeks. A total of 1169 persons underwent randomization: 578 were assigned to the solanezumab group and 591 to the placebo group. The mean age of the participants was 72 years, approximately 60% were women, and 75% had a family history of dementia. At 240 weeks, the mean change in PACC score was −1.43 in the solanezumab group and −1.13 in the placebo group (difference, −0.30; 95% confidence interval, −0.82 to 0.22; P=0.26). Amyloid levels on brain PET increased by a mean of 11.6 centiloids in the solanezumab group and 19.3 centiloids in the placebo group. Amyloid-related imaging abnormalities (ARIA) with edema occurred in less than 1% of the participants in each group. ARIA with microhemorrhage or hemosiderosis occurred in 29.2% of the participants in the solanezumab group and 32.8% of those in the placebo group. Solanezumab, which targets monomeric amyloid in persons with elevated brain amyloid levels, did not slow cognitive decline as compared with placebo over a period of 240 weeks in persons with preclinical Alzheimer’s disease. (Funded by the National Institute on Aging and others; A4 ClinicalTrials.gov number, NCT02008357.) QUICK TAKE VIDEO SUMMARYSolanezumab in Preclinical Alzheimer’s Disease 02:05
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly a trial of solanezumab did not slow cognitive decline in people with pre-clinical Alzheimer's disease , did not affect amyloid plaque level but influenced CDR-SB in line with the other studies (0.34). (498) (497)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [498]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“approximately 30% of participants in either group progressed to symptomatic AD (stage 3 or stage 4 of AD).”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The A4 (Anti-Amyloid treatment in Asymptomatic Alzheimer’s disease) study, a 5-year clinical trial examining the effects of solanezumab in asymptomatic individuals with amyloid accumulation, failed to show significant cognitive benefits.14”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most importantly, the participants who eventually progressed, in fact, had higher levels of accumulated Aβ42 levels measured in post-treatment PET.”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While recent clinical trials of anti‐amyloid therapies, such as donanemab and lecanemab, 2 , 3 have shown promising results, the failures of earlier treatments like solanezumab and bapineuzumab indicate that targeting a single AD‐specific pathological process is insufficient to mitigate cognitive decline. 4 , 5 , 6”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [4]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“In a more recent phase 3 trial (NCT02008357), solanezumab failed to meet primary and secondary outcomes, as the drug did not slow cognitive decline in preclinical AD or reduce the risk of progression to symptomatic AD [80].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [80]
The cited source says what the claim attributes to it.
In the citing paper
“Despite a well-defined study population and an extended treatment period, results indicated no substantial difference in cognitive decline between the treatment and placebo groups.”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“The A4 study was designed to test whether solanezumab could slow cognitive decline by targeting monomeric amyloid in preclinical AD, but the trial showed no significant effect compared to placebo. 4”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“The A4 study was a multicenter, Phase 3, double‐blind, placebo‐controlled study in subjects with preclinical AD. 4”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citation
Research works printed but not linked: 3
- Wechsler D. WMS-R: Wechsler Memory Scale–Revised: manual. San Antonio, TX: Psychological Corporation, 1987.
- Wechsler D. Wechsler Adult Intelligence Scale–Revised. San Antonio, TX: Psychological Corporation, 1981.
- Genentech. Genentech provides update on phase III GRADUATE program evaluating gantenerumab in early Alzheimer’s disease. November 13 2022 (https://www.gene.com/media/press-releases/14974/2022-11-13/genentech-provides-update-on-phase-iii-g).
Cited by
Sorted by citations
Items 301–400 of 430
Donohue, M., Insel, P. S., & Langford, O. (2025) · Statistics in Medicine · doi:10.1002/sim.70058 · Cited by 1
Self-citationAPP β-CTF triggers cell-autonomous synaptic toxicity independent of AβPreprint
Luo, M., Zhou, J., Sun, C., Chen, W., Fu, C., Si, C., Zhang, Y., Geng, Y., & Chen, Y. (2025) · eLife · doi:10.7554/elife.100968.2 · Cited by 2
Localization of Network-Level Atrophy in Preclinical Alzheimer's DiseasePreprint
Lee, S., Baratono, S. R., Burt, G., Palm, S. T., Drew, W., Zide, B. S., Chiulli, N., Larivière, S., Fox, M., Sperling, R. A., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-5977523/v1 · Cited by 1
Self-citationMulti-organ MRI digitizes biological aging clocks across proteomics, metabolomics, and geneticsPreprint
Cao, H., Song, Z., Duggan, M. R., Erus, G., Srinivasan, D., Tian, Y., Bai, W., Rafii, M. S., Aisen, P. S. S., Belsky, D. W., et al. (2025) · medRxiv · doi:10.1101/2025.07.10.25331263 · Cited by 1
Self-citationKhorsand, B., Ghanbarian, E., Rabin, L. A., Sajjadi, S. A., & Ezzati, A. (2025) · medRxiv · doi:10.1101/2025.07.22.25332015 · Cited by 1
Strategies for Neuroprotection in Alzheimer's Disease
Jasutkar, H. G. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch5 · Cited by 1
Performance of Elecsys pTau217 plasma immunoassay to detect brain amyloid pathologyPreprint
Hibar, D. P., Bauer, A., Rabe, C., Borlinghaus, N., Jethwa, A., Kollmorgen, G., Domenico, A. D., Zetterberg, H., Blennow, K., Masters, C. L., et al. (2025) · medRxiv · doi:10.1101/2025.08.08.25333024 · Cited by 1
Self-citationCerebrospinal fluid proteomics for predictive assessment of Alzheimer’s Disease riskPreprint
Rathore, S., Dammer, E. B., Shantaraman, A., Wu, F., Duong, D. M., Fox, E. J., Johnson, E. C. B., Lah, J. J., Initiative, A. D. N., Seyfried, N. T., et al. (2025) · medRxiv · doi:10.1101/2025.10.24.25337921 · Cited by 1
Ellis, R. J., Airaud, A., Jasodanand, V. H., Kowshik, S. S., Bellitti, M., Kolachalama, V. B., Estiri, H., Glymour, M. M., Dufouil, C., Sperling, R. A., et al. (2025) · medRxiv · doi:10.1101/2025.11.19.25340533 · Cited by 1
Self-citationClinical and Pathological Progression of Awareness Trajectories in Preclinical Alzheimer’s DiseasePreprint
López‐Martos, D., Sánchez‐Benavides, G., Grau‐Rivera, O., Amariglio, R. E., Dubbelman, M. A., Gatchel, J. R., Marshall, G. A., Diez, I. P., Vannini, P., & study, T. A. (2026) · medRxiv · doi:10.64898/2026.02.16.26346402 · Cited by 1
Self-citationMorbus Alzheimer: Antikörper Solanezumab ohne Wirkung im präklinischen Stadium
Simon, A. (2023) · Neurologie up2date · doi:10.1055/a-2147-2306
Introduction to the Special Issue on the A4 Study
Aisen, P. S. S., & Sperling, R. A. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.118
Self-citationYaari, R., Holdridge, K. C., Mancini, M., Rafii, M. S., Case, M., Battioui, C., Sims, J. R., Aisen, P. S., & Sperling, R. A. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.138
Self-citationUse of robust norming to create a sensitive cognitive summary score in de novo Parkinson’s diseasePreprint
Weintraub, D. A., Brumm, M. C., Kurth, R., York, M. K., & Initiative, T. P. P. M. (2024) · medRxiv · doi:10.1101/2024.07.08.24310076
Psychotherapieerfolg: Benefit durch Personalisierung?
(2024) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2304-1518
Morbus Alzheimer: Antikörper Solanezumab ohne Wirkung im präklinischen Stadium
(2024) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2304-0921
A Machine Learning Approach to Predict Cognitive Decline in Alzheimer’s Disease Clinical TrialsPreprint
Nallapu, B. T., Petersen, K. K., Qian, T., Demirsoy, İ., Ghanbarian, E., Davatzikos, C. A., Lipton, R. B., Ezzati, A., & Initiative, A. D. N. (2024) · medRxiv · doi:10.1101/2024.09.03.24312481
Exploring the Relationship Between Amyloid Burden and Depression in Pre-clinical Alzheimer’s Disease
Benyahia, S. A., Kahlon, S., Rijnhart, J. J. M., & Bishnoi, R. J. (2024) · Cureus · doi:10.7759/cureus.69716
Erichsen, P. A. (2024) · Adverse Drug Reaction Bulletin · doi:10.1097/fad.0000000000000077
Searching for new drugs to treat Alzheimer’s disease dementia through multiple pathways
Bai, H., & Feng, X.-F. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i1.100833
Murshid, N. M., Sahardi, N. F. N. M., & Makpol, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010241
Immunotherapy for Alzheimer's disease: advances in adaptive immunity
Zhi, T. (2025) · New discovery. · doi:10.61958/ndfs3904
An, D., Li, X., & Xu, Y. Y. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111576
Biological Aspects of Transcranial Magnetic Stimulation in Neurocognitive Disorders
Lu, H. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_56-1
Anti-Amyloid Agents: A Self-Fulfilling prophecy
Giannakis, A., & Konitsiotis, S. (2025) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2025.111338
Sato, K., Ihara, R., Niimi, Y., Suzuki, K., Iwata, A., & Iwatsubo, T. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251349188
Self-citationThe Protective Mechanism of ApoE3 R136S in Alzheimer’s Disease: A New Hope for Neurodegeneration
Luo, R., & Guo, K. (2025) · Phenomics · doi:10.1007/s43657-025-00253-6
Revisiting Centiloids using AIPreprint
Bourgeat, P., Fripp, J., Lebrat, L., Xia, Y., Feizpour, A., Cox, T. O., Zisis, G., Gillman, A., Goyal, M. S., Tosun, D., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7015694/v1
Self-citationRelationship between BrainAge Polygenetic Risk Score and plasma biomarkers in the A4/LEARN studiesPreprint
Condado, J. G., Seto, M., Cuppels, M., Birkenbihl, C. J., Klinger, H. M., Coughlan, G., Properzi, M. J., Yang, H., Schultz, A. P., Chhatwal, J. P., et al. (2025) · medRxiv · doi:10.1101/2025.07.07.25331010
Self-citationAckley, S. F., Flanders, M., Murchland, A. R., Chen, R., Wang, J., Shah, S. J., Huey, E. D., & Glymour, M. M. (2025) · medRxiv · doi:10.1101/2025.07.21.25331942
Biological Aspects of Transcranial Magnetic Stimulation in Neurocognitive Disorders
Lu, H. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_56
Tau-Connectome Subtypes and Solanezumab Response in Preclinical Alzheimer’s DiseasePreprint
Abuwarda, H., Tsai, W., Ding, S., Elhassan, M. O. E., Shen, X., Zhao, Y., Constable, R. T., & Fredericks, C. A. (2025) · medRxiv · doi:10.1101/2025.09.13.25335690
Nencha, U., & Hummel, F. C. (2025) · Clinical and Translational Neuroscience · doi:10.3390/ctn9030043
Wang, G., Shan, G., Li, Y., Liao, Y., Schneider, L. S. S., & Cutter, G. (2025) · Statistics in Medicine · doi:10.1002/sim.70266
RNA virus and DNA virus initiations of autoimmune diseases and/or dementias
Roe, K. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104481
Zhu, C. W., Flournoy, C., Raman, R., & Sano, M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70641
Self-citationHypothesis-Driven Insights and Clinical Trial Updates in Alzheimer’s Disease Pathogenesis
Alhawarri, M. B. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273387383250924031644
Antimicrobial peptides act as a component of brain immunity against microbes in Alzheimer’s disease
Chandrashekar, M., Velmurugan, G., Mishra, A., & Chinnathambi, S. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.016
Seto, M., Klinger, H. M., Clifton, M. J., Janve, V. A., Brown, J. A., Birkenbihl, C., Coughlan, G., Townsend, D. L., Wang, T., Properzi, M. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.21.689770
Self-citationAutomatic Quality Control for Resting‐State BOLD‐Based Cerebrovascular Reactivity Mapping
Wang, Y., Liu, P., Li, M., Hou, X., Lu, H., Wu, D., Lin, Z., & Initiative, A. D. N. (2025) · NMR in Biomedicine · doi:10.1002/nbm.70208
MEGF10 knockout promotes cortical and hippocampal amyloid deposition in AD mouse model
Fujita, Y., Yabe, T., Yamada, Y., Kiuchi, R., Nagase, M., Nakamori, R., Ichikawa, S., Obara, T., Yasuda, H., Kurano, J., et al. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138487
Jin, K. L., Chezem, W. R., & Wang, G. (2025) · medRxiv · doi:10.64898/2025.12.10.25341978
Li, R., Langford, O., Insel, P. S., Sperling, R. A., Raman, R., Aisen, P. S. S., & Donohue, M. (2025) · medRxiv · doi:10.64898/2025.12.15.25342305
Self-citationDumitrascu, O. M., Doustar, J., Fuchs, D.-T., Koronyo, Y., Sherman, D. S., Miller, M. S., Johnson, K., Carare, R. O., Verdooner, S. R., Lyden, P. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26129708
Self-citationProtocol for the Asian Cohort for Alzheimer's Disease (ACAD) Study
Ho, P., Peavy, G. M., Lee, H., Gu, Y., Kukull, W. A., Choi, Y., Yu, W. H., Reyes‐Dumeyer, D., Henderson, V. W., Tee, B. L., et al. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70189
Neuropathologically validated MRI to tau PET synthesis via Covariate-modulated attention networksPreprint
Borhi, M., Lyu, R.-K., Jagust, W. J., Wang, J., Giorgio, J., & Initiative, A. D. N. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.27.696668
Nakashima, S., Sato, K., Niimi, Y., Ihara, R., Ikeuchi, T., Ishii, K., Ito, K., Iwata, A., Kasuga, K., Kato, T., et al. (2026) · Alzheimer's & Dementia · doi:10.1002/dad2.70242
Self-citationLessons from the Colombian kindred: rethinking Alzheimer's prevention
Fortea, J., Llibre‐Guerra, J. J., O’Connor, A., & Levin, J. (2026) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00481-8
Plasma-driven disassembly of amyloid-β aggregates by the interplay of physicochemical stimuli
Jo, Y., Bae, J. H., Jang, J., Lee, H., Heo, Y., Lee, Y. H., Park, C. B., & Park, S. (2026) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2025.103090
A Two‐Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p‐Tau217 Gray Zone
Parankusham, H. S., Vanderlip, C. R., Birkenbihl, C. J., Krishna, E., Ugboaja, C., Budson, A. E., Frank, B. E., & Initiative, A. D. N. (2026) · Annals of Clinical and Translational Neurology · doi:10.64898/2026.02.03.26345302 · Cited by 1
Cognitive screening biases in a secondary prevention Alzheimer's disease clinical trial
Sai, I., Grill, J. D., Younes, K., Winer, J. R., Cody, K. A., Sperling, R. A., Mormino, E. C., & Young, C. B. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71254
Self-citationExploiting Information Discrepancy in Multi-Modal Data for Alzheimer’s Disease Classification
Li, Y., Li, Y., Zhang, L., Wang, Y., & Zhan, Q. (2026) · IEEE Access · doi:10.1109/access.2026.3673063
Programmed cell death: a promising management for Alzheimer’s disease
Yang, Q., Ren, X., Jia, R., Zheng, L., Ou, R., Xu, Y., Luo, Y., Yang, G., & Wang, X. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02330-1
Liao, Y., Shen, C., Sun, L., Ding, P., Luo, L., & Luo, J. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109065
Kaur, N., Gupta, S., Bansal, G., & Bansal, Y. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11546-x · Cited by 2
Kwon, S., Lee, S., Siegel, J. S., Chiulli, N., Freedberg, M., Hebscher, M., Hendrikse, J. J., Hermiller, M. S., Ji, G., Tambini, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.10.717784
Olson, C., Bravo, M. M. G., González, G., & Camp, M. E. (2026) · Focus · doi:10.1176/appi.focus.20250042
Recent Advances in Drug Development for the Management of Alzheimer’s Disease
Upadhyay, A., Singh, A. K., Jayaswal, N., Jaiswal, P., Singh, S. N., & Tewari, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010014
Yang, B., Earnest, T., Bilgel, M., Albert, M., Johnson, S. C., Davatzikos, C. A., Erus, G., Masters, C. L., Resnick, S. M., Miller, M. I., et al. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.04.005
Self-citationJiang, Y., Ding, Y., Cao, Q., Wu, X., Li, X., Xu, Y., Zhao, Z., Xu, M., Lu, J., Wang, T., et al. (2026) · General Psychiatry · doi:10.1002/gps3.70013
Wang, D., Yan, S., Zhou, R., Li, Y., Liu, L., Wei, Y., Wang, D., Yao, H., Zhou, B., Lu, J., et al. (2026) · Science Advances · doi:10.1126/sciadv.aef3787
He, D., Langhough, R. E., Jonaitis, E., Wilson, R., Hermann, B., Zetterberg, H., Johnson, S. C., & Mueller, K. (2026) · Brain Communications · doi:10.1093/braincomms/fcag163
The clinical value of multimodal neuroimaging in monoclonal antibody therapy for Alzheimer's disease
Wang, Y., Li, H., Zhou, J., Zhao, S., Yang, A., & Li, Z. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1761380
Gut Dysbiosis in Alzheimer’s Disease: Insights from the Microbiome
Kiran, N. S., Yashaswini, C., Chatterjee, A., & Prajapati, B. G. (2026) · Springer eBooks · doi:10.1007/978-981-95-7494-0_11
Elorriaga, I. T., Jiménez-Marín, A., Diez, I. P., Erramuzpe, A., & Cortés, J. M. (2026) · medRxiv · doi:10.64898/2026.05.11.26352893
Moëlo, C., Kronqvist, N., & Johansson, J. (2026) · Advanced Biology · doi:10.1002/adbi.202500721
Patterson, C., Chattopadhyay, T., Thomopoulos, S. I., Saykin, A. J., Davatzikos, C. A., Mormino, E. C., Tosun, D., Beecham, G. W., Biber, S., Kukull, W. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.2139/ssrn.6791127
Hao, L., Xing, Y., & Han, Y. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261453551
The end of semiology, or the rise of precision overdiagnosis?
Tiwa, T. M., Sengkey, S. B., Sengkey, M. M., Pandolos, T., & Padillah, R. (2026) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2026.126027
Hill, C., Morgan, H., Michopoulou, S. K., Niranjan, M., & Kipps, C. (2026) · medRxiv · doi:10.64898/2026.05.30.26354521
Xiao, C., Ard, T. D., Blazhenets, G., Joie, R. L., Pappas, I., Toga, A. W., Initiative, T. F. L. D. N., & The Health and Aging Brain Study (HABS‐HD) Study Team (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71586
Szewczyk, O., Wojsław, M., & Pstrągowski, M. (2026) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2026-0005
Li, H., Liu, S., Luo, Z., & Wang, T. (2026) · Research Square · doi:10.21203/rs.3.rs-9932977/v1
López‐Martos, D., Suárez‐Calvet, M., Salvadó, G., Cacciaglia, R., Shekari, M., González‐Escalante, A., Horta‐Barba, A., Palma‐Gudiel, H., Milà‐Alomà, M., Brugulat‐Serrat, A., et al. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.06.006
Terman, E. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1841695
Wu, Y., Di, Y., Wang, H. W., Wang, L., Zhang, J., Zhang, Y., & Lyu, D. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103216
Royall, D. R., Palmer, R. F., & Initiative, A. D. N. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261458678
Atrophy in preclinical Alzheimer’s disease maps to a network that predicts longitudinal decline
Lee, S., Baratono, S. R., Ha, J.-H., Burt, G., Palm, S. T., Drew, W., Zide, B. S., Chiulli, N., Larivière, S., Zhang, S., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03706-0 · Cited by 2
Self-citationSubtyping and staging of Alzheimer’s disease from routine structural MRI with PHASE–ADPreprint
Baumeister, H., Lüsebrink, F., Kleineidam, L., Hansen, N., Schmid, M., Moscoso, A., Leuzy, A., Mastenbroek, S. E., Groot, C., Brosseron, F., et al. (2026) · medRxiv · doi:10.64898/2026.06.26.26356678
Hunting for an Antigen: Humoral Immunity in Alzheimer’s Disease
Delgado, A. M., Greer, B. D., Maul, R. W., & Gearhart, P. J. (2026) · Cells · doi:10.3390/cells15131227
Relationships between longitudinal retinal amyloid imaging and amyloid PET in the A4 Trial
Sukreet, S., Donohue, M., Ngolab, J., Belsha, A., Salazar, J., Cohen, P., Jaiswal, S., Tan, V., Aggarwal, N. T., Alber, J., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70422
Self-citationKim, S., Oda, H., Oyama, R., Makishi, R., Bade, S., Bade, S., Ally, I., Iijima, Y., Gibo, Y., Minami, K., et al. (2026) · BJPsych Open · doi:10.1192/bjo.2026.12044
Defining and Measuring Cognitive Decline and Clinical Relevance
Kurz, C., NEWHOUSE, P. A., Wyman‐Chick, K. A., Galvin, J. E., Lautenschlager, N. T., & Sabbagh, M. N. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-00996-y
BBB-Nuke: Transport-Aware Prediction of Blood-Brain Barrier Penetration in Small MoleculesPreprint
Abasciano, N., Hadipour, H., Poddar, A., Rudrum, J., & Sobodu, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.13.738280
The Promise and Peril of Alzheimer Disease Prevention
Grill, J. D., & Graff‐Radford, J. (2026) · Neurology · doi:10.1212/wnl.0000000000218348
Singhal, M., Lin, J., Delehanty, M., Karimi, A., Rittner, L., & Bento, M. (2026) · Digital Health · doi:10.1177/20552076261470698
Prognostic value of plasma %p‐tau217 in cognitively unimpaired older adults
Silva‐Rodríguez, J., Zhang, L., Kleineidam, L., López‐González, F. J., Wagner, S., Martinez-Castillo, M., Sogorb‐Esteve, A., Guamán‐Chulunchana, M. E., Pastor, A. B., Moreno, N., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71599
Sustaining Drug Discovery Amid the Limits of Alzheimer's Disease Immunotherapies
McDiarmid, A. (2026) · eNeuro · doi:10.1523/eneuro.0112-26.2026
Periyasamy, T. S., Sekar, N., & Lakshmanan, H. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261471812
Zhang, X., Zhuang, D., Lai, C., Zheng, C., Soh, Z. D., Wagner, S. K., Cai, V. Y., Yang, Z., Wang, S., Geng, X., et al. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101504
Zhu, Q., & Yu, H. B. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c01001
Stages of objective memory impairment (SOMI) as a predictor of clinical progression in the A4 study
Kumari, P., Lipton, R. B., Aschenbrenner, A. J., Sperling, R. A., Donohue, M., & Grober, E. H. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100641
Self-citationBayly, H., Salvati, L. R., Lenio, S., Mez, J., Alosco, M. L., & Tripodis, Y. (2026) · Journal of Aging Research and Lifestyle · doi:10.1016/j.jarlif.2026.100081
Parveen, N., Ansari, J. A., Singh, M., & Verma, V. (2026) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-026-01211-3
Benchmarking privacy and utility in synthetic tabular cohorts for Alzheimer's disease research
Winzell, F., Arvidsson, I., Overgaard, N. C., Heyden, A., Åström, K., Karlsson, L., Vogel, J. W., Hansson, O., Mattsson, N., & Initiative, A. D. N. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70430
The Dementia Trials Accelerator (DTA): a UK dementia trials-ready cohortPreprint
Whiteley, W. N., van Duijn, C. M., Postlethwaite, N., Beal, E., Bennett, K., Blakoe, G., Brooks, H., Collet, K., Elliott, P., Forde, E., et al. (2026) · medRxiv · doi:10.64898/2026.08.14.26359869
Чи існує продромальна фаза розсіяного склерозу?
(2026) · Український медичний часопис · doi:10.32471/umj.1680-3051.279939
Emanuele, E., & Minoretti, P. (2026) · The FASEB Journal · doi:10.1096/fj.202601680rr
Current treatments for dementias
Spires‐Jones, T. L. (2026) · Oxford University Press eBooks · doi:10.1093/9780198995296.003.0006
Jaskulski, K., Kowalenko, K., Szadkowski, J., Wichman, K., Kasprzak, H., Lavrenchuk, Y., Drobinska, N., Leśniak, N. M., Leśniak, J. A., & Olszowiec, Z. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6427
Metadata
- Authors
- Sperling, R. A., Donohue, M. C., Raman, R., Rafii, M. S., Johnson, K., Masters, C. L., van Dyck, C. H., Iwatsubo, T., Marshall, G. A., Yaari, R., Mancini, M., Holdridge, K. C., Case, M., Sims, J. R., & Aisen, P. S.
- Affiliations
- University of Southern California (US)
- From the Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School (R.A.S., G.A.M.), and the Departments of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School (K.J.) — both in Boston; Alzheimer’s Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego (M.C.D., R.R., M.S.R., P.S.A.); the Florey Institute, University of Melbourne, Melbourne, VIC, Australia (C.L.M.); the Departments of Psychiatry, Neurology, and Neuroscience, Yale School of Medicine, New Haven, CT (C.H.D.); the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, Tokyo (T.I.); and Eli Lilly, Indianapolis (R.Y., M.M., K.C.H., M.C., J.R.S.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1096-1107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10559996
- OpenAlex
- W4384523451
- Cited by
- 429
- References
- 36
- Citations by year
- 2026: 140 · 2025: 153 · 2024: 115 · 2023: 21
- FWCI
- 76.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Alzheimer’s Association
- Accelerating Medicines Partnership through the Foundation for the National Institutes of Health
- GHR Foundation
- Davis Alzheimer Prevention Program
- anonymous foundation
- National Institute on Aging (R01AG063689, U19AG010483, U24AG057437)
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- solanezumab, preclinical Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, cognitive decline, amyloid PET, 18F-florbetapir, amyloid-related imaging abnormalities, aria, Alzheimer's disease prevention, brain amyloid burden
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Amyloid beta-Peptides, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
